Galmed Pharmaceuticals Lt... (GLMD)

NasdaqCM: GLMD · Precio en tiempo real · USD

4.48

+0.00 (0.00%)

Al cierre: Aug 19, 2026, 4:03 PM

0.00% (1D)

No hay datos disponibles

Precio de compra	0.39
Capitalización de mercado	4.9M
Ingresos (TTM)	n/a
Beneficio neto (TTM)	-11.12M
Beta	0.68
EPS (TTM)	-16.48
Ratio PER (TTM)	n/a
Adelante PE	-4.6
P/B (TTM)	2.24
P/S (TTM)	n/a
Earnings Date	n/a

Precio de venta	0.68
Volumen	177,165
Volumen medio (20D)	96,523
Abierto	5.38
Anterior Cerrar	4.48
Rango del día	4.10 - 5.45
Rango de 52 semanas	3.29 - 13.20
analista	n/a
Precio objetivo	n/a
Dividendos	n/a
Fecha ex dividendo	n/a

Acerca de GLMD

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases and related indications. The company develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in a Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The comp...

[Leer más]

Industria Biotechnology

Sector Healthcare

IPO Fecha Mar 13, 2014

Empleados 3

Bolsa de Valores NasdaqCM

Símbolo bursátil GLMD

Sitio web https://galmedpharma.com

Perfil completo de la empresa

Desempeño financiero

En 2025, los ingresos de Galmed Pharmaceuticals fueron 0, un aumento de undefined% en comparación con 0 del año anterior. Las ganancias fueron -10.31M, un aumento de 37.14%.

Estados financieros

Sorpresa de resultados

Galmed Pharmaceuticals ha publicado sus resultados trimestrales en Jul 8, 2026:

Ingresos de $0 falla las estimaciones por $0, con NaN% Crecimiento interanual.

EPS de -0.29 supera las estimaciones en 0.09, con 53.23% Crecimiento interanual.

Noticias

1 mes hace · InvestorsHub

Galmed Develops Cardiac-Targeted Aramchol Formulation to Expand Cardiovascular Pipeline (NASDAQ:GLMD)

Galmed announced the development of a lipid nanoparticle formulation of Aramchol designed to target heart tissue, marking a potential expansion of the drug beyond its existing liver and gastrointestin...

8 meses hace · Associated Press Finance

Galmed Pharmaceuticals: Q3 Earnings Snapshot

RAMAT GAN, Israel (AP) — Galmed Pharmaceuticals Ltd. (GLMD) on Wednesday reported a loss of $1.9 million in its third quarter. The Ramat Gan, Israel-based company said it had a loss of 33 cents per sh...

9 meses hace · Associated Press Finance

BC-Most Active Stocks

HIVE Digital Technologies Ltd. 30,450,329 3.7899

11 meses hace · Associated Press Finance

Galmed Pharmaceuticals: Q2 Earnings Snapshot

RAMAT GAN, Israel (AP) — Galmed Pharmaceuticals Ltd. (GLMD) on Thursday reported net income of $2.5 million in its second quarter. On a per-share basis, the Ramat Gan, Israel-based company said it had...